Affiliation:
1. Scientific Research Clinical Institute of Pediatrics and Pediatric Surgery named after Academician Yu.E. Veltishchev Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N.I. Pirogov Ministry of Health of the Russian Federation
2. Research Clinical Institute of Childhood, Ministry of Health of the Moscow Region
Abstract
Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is a complex clinical disease with an estimated worldwide prevalence of 1-15%. The transmission routes for HCV and HBV are similar. During co-infection, four serological profiles are observed: codominant, HCV dominant, HBV dominant and non-replicative. Although both HBV and HCV replicate in hepatocytes, their life cycles are quite different. Viral replication in co-infected cells is characterized by the dominance of HCV replication over HBV replication. Three theories of interaction between HCV and HBV are discussed. There are no established recommendations for the treatment of HBV/HCV co-infection. Treatment of chronic hepatitis C without HBV suppression increases the risk of HBV reactivation. In the review, we evaluate studies of both direct-acting antivirals and interferon-based therapies. Screening and prevention of co-infection are important to prevent serious HBV reactivation.
Publisher
LLC Global Media Technology
Reference35 articles.
1. Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018;6(3):296-305. doi: 10.14218/JCTH.2018.00016.
2. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221-228.
3. Rodriguez-Iñigo E., Bartolomé J., Ortiz-Movilla N. et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol. 2005;79:15578-15581. doi: 10.1128/JVI.79.24.15578-15581.2005.
4. Pol S., Haour G., Fontaine H., Dorival C. et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017;46(11-12):1054-1060. doi: 10.1111/apt.14352.
5. Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N. An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother. 2017;18:1691-1702. doi: 10.1080/14656566.2017.1398233.